Overall, this is likely due to glycosylation’s dual effects of stabilizing PD-L1 and facilitating the interaction between PD-1 and PD-L1, which inhibits the immune functions of T-cells in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.